

BEIKE BIOTECHNOLOGY

A Descriptive Statistical Report on 36 Multiple Sclerosis Cases with Cell Therapy From 2006 through 2009

Background

This descriptive report covers subjective information collected by questionnaires from our overseas MS patients confirmed before the hospital-admission. Participating patients were treated between 2006 and 2009. This information mainly includes the efficacy assessment of the cell therapy on five time points: immediately after the treatment, one month, three months, six months, and twelve months after the treatment. The data for this analysis is based solely on patients who submitted the questionnaire to our followup department.

Results

General Effectiveness: General effectiveness was measured by a Yes/No question asked to the patient and/or patient's caregiver. The question asked if the patient had any improvement at any time after the treatment. Of patients that responded to the questionnaire, the general effectiveness is 27 out of 36 patients (75%).


Improvement Immediately After the Treatment: The effectiveness rate at the time point immediately after the treatment is 24 out the 36 patients (66.7%).

Improvement at 1 Month, 3 Months, 6 Months, and 12 months: There were two patients at one month and one patient at 3 months after the treatment that received their first improvements at these time points. A representation of these numbers can be seen on page two in Chart 1. No patients who responded to the questionnaire gained their first improvements at six or 12 months.

Conclusions

For the 36 patients, the general effectiveness percentage is 75% (percent of total patients that received improvement). 24 out of 36 patients received improvements immediately after treatment, while three out of the 36 patients received their first improvements at or after the one month period. Thus it appears significant that a majority of patients that received improvements observed them right away. Patients receiving no improvements by the time of discharge had little probability of gaining any after this time.

Chart 1: When Patients First Noticed Improvement (After Treatment)



■ Number of patients that noticed their first improvements at this time

Disclaimer: The information contained in this document is to be used solely as a reference for observing patients' subjective opinions and observations about treatment efficacy.

BEIKE BIOTECHNOLOGY CO., LTD.

International Office

Flat 601, Unit 2, Bldg 4, Da Gong Hai An
48 Dong Hai Xi Road
Qingdao, China 266071

Head Office

9th Floor, Zhongke Building, 1 South Street
South Area, Shenzhen Hi-Tech Industrial Park
Shenzhen, China 518057

Tel: +86 532-6677-6659 Fax: +86 532-8577-9113
www.beikebiotech.com